Australia is eagerly anticipating the arrival of retatrutide, a cutting-edge dual GIP and GLP-1 receptor agonist , representing a potential advance in obesity treatment . Early research findings have https://desert-stardust-mushroom728949.healthlineblog.com/90735/retatrutide-in-australia-a-potential-breakthrough-for-weight-loss